Recently, Hickey et al. demonstrated that AR performs a tumor suppressor role in the ER-positive BC subtype, and the AR activation induces potent antitumor activity in multiple disease contexts, including resistance to endocrine therapy and CDK4/6 inhibitors. Here, CDK4 is linked to neoplasm.